Phages, fitness, virulence, and synergy: A novel approach for the therapy of infections caused by Pseudomonas aeruginosa

Journal of Infectious Diseases

Volumn 215, Issue 5, 2017, Pages 668-670

  Stratton, Charles W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antimicrobial therapy; Combination therapy; Endocarditis; Fitness; Phage therapy; Pseudomonas aeruginosa; Rat aortic endocarditis model; Synergy; Virulence

Indexed keywords

CIPROFLOXACIN; MEROPENEM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIAL FITNESS; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATION; EDITORIAL; HOSPITAL INFECTION; HUMAN; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PHAGE; BACTERIOPHAGE; ENDOCARDITIS; PHAGE THERAPY; VIRULENCE;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; ENDOCARDITIS; HUMANS; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; VIRULENCE;

EID: 85019864422     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw634     Document Type: Editorial

References (39)

1. Kerr KG, Snelling AM. Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect 2009; 73:338-44
2. Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 2013; 67:159-73
3. Loveday HP, Wilson JA, Kerr K, Pitchers R, Walker JT, Browne J. Association between healthcare water systems and Pseudomonas aeruginosa infections: a rapid systematic review. J Hosp Infect 2014; 86:7-15
4. Walker J, Moore G. Pseudomonas aeruginosa in hospital water systems: biofilms, guidelines, and practicalities. J Hosp Infect 2015; 89:324-7
5. Cross A, Allen JR, Burke J, et al. Nosocomial infections due to Pseudomonas aeruginosa: review of recent trends. Rev Infect Dis 1983; 5 Suppl 5:S837-45
6. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103:e39
7. Werth BJ, Carreno JJ, Reveles KR. Shifting trends in the incidence of Pseudomonas aeruginosa septicemia in hospitalized adults in the United States from 1996-2010. Am J Infect Control 2015; 43:465-8
8. Strateva T, Yordanov D. Pseudomonas aeruginosa-A phenomenon of bacterial resistance. J Med Microbiol 2009; 58:1133-48
9. Lister PD, Wolter DJ, Hanson ND. Antibacterialresistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22:582-610
10. McCarthy K. Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy. Semin Respir Crit Care Med 2015; 36:44-55
11. Oliver A, Mena A. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin Microbiol Infect 2010; 16:798-808
12. Roux D, Danilchanka O, Guillard T, et al. Fitness cost of antibiotic susceptibility during bacterial infection. Sci Transl Med 2015; 7:297ra114
13. Montanari S, Oliver A, Salerno P, et al. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 2007; 153(Pt 5):1445-54
14. Skurnik D, Roux D, Cattoir V, et al. Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing. Proc Natl Acad Sci U S A 2013; 110:20747-52
15. Perez-Gallego M, Torrens G, Castillo-Vera J, et al. Impact of AmpC derepression on fitness and virulence: the mechanism or the pathway? MBio 2016; 7:e01783-16
16. Agnello M, Finkel SE, Wong-Beringer A. Fitness cost of fluoroquinolone resistance in clinical isolates of Pseudomonas aeruginosa differs by type III secretion genotype. Front Microbiol 2016; 7:1591
17. Kaiser SJ, Mutters NT, DeRosa A, Ewers C, Frank U, Gunther F. Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation. Eur J Clin Microbiol Infect Dis 2017; 36(2):243-53
18. Zowalaty ME, Thani AA, Webster TJ, et al. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. Future Microbiol 2015; 10:1683-706
19. Chatterjee M, Anju CP, Biswas L, Anil Kumar V, Gopi Mohan C, Biswas R. Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int J Med Microbiol 2016; 306:48-58
20. Ceyssens PJ, Lavigne R. Bacteriophages of Pseudomonas. Future Microbiol 2010; 5:1041-55
21. Knezevic P, Obreht D, Curcin S, et al. Phages of Pseudomonas aeruginosa: response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation. J Appl Microbiol 2011; 111:245-54
22. Betts A, Vasse M, Kaltz O, Hochberg ME. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol Appl 2013; 6:1054-63
23. Krylov VN. Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy. Adv Virus Res 2014; 88:227-78
24. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 2015; 89:7449-56
25. Torres-Barcelo C, Arias-Sanchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One 2014; 9:e106628
26. Torres-Barcelo C, Franzon B, Vasse M, Hochberg ME. Long-term effects of single and combined introductions of antibiotics and bacteriophages on populations of Pseudomonas aeruginosa. Evol Appl 2016; 9:583-95
27. Lindberg HM, McKean KA, Wang IN. Phage fitness may help predict phage therapy efficacy. Bacteriophage 2014: 4:e96081
28. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep 2016; 6:26717
29. Oechslin F, Piccardi P, Mancini S, et al. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis 2017; 215:703-12
30. Rybak MJ, Houlihan HH, Mercier RC, Kaatz GW. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41:1359-63
31. Heraief E, Glauser MP, Freedman LR. Natural history of aortic valve endocarditis in rats. Infect Immun 1982; 37:127-31
32. Carbon C. Experimental endocarditis: a review of its relevance to human endocarditis. J Antimicrob Chemother 1993; 31:71-85
33. Carbon C, Cremieux AC, Fantin B. Pharmacokinetic and pharmacodynamic aspects of therapy of experimental endocarditis. Infect Dis Clin North Am 1993; 7:37-51
34. Calza L, Manfredi R, Chiodo F. Infective endocarditis: a review of the best treatment options. Expert Opin Pharmacother 2004; 5:1899-916
35. Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. Lancet 2012; 379:965-75
36. Reyes MP, Ali A, Mendes RE, Biedenbach DJ. Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008. Medicine (Baltimore) 2009; 88:294-301
37. Dawson NL, Brumble LM, Pritt BS, Yao JD, Echols JD, Alvarez S. Left-sided Pseudomonas aeruginosa endocarditis in patients without injection drug use. Medicine (Baltimore) 2011; 90:250-5
38. Gordo I, Perfeito L, Sousa A. Fitness effects of mutations in bacteria. J Mol Microbiol Biotechnol 2011; 21:20-35
39. Rose T, Verbeken G, Vos DD, et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma 2014; 4:66-73